StockData
CytoMed Therapeutics Ltd logo

CytoMed Therapeutics Ltd (GDTC) company profile

GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$0.78+0.01 (+1.18%)

Close on Nov 17, 2026Market cap $9.26MP/E –Yield –

About CytoMed Therapeutics

Pharmaceutical Preparations, SIC 2834

CytoMed Therapeutics Limited is a biopharmaceutical company focused on developing cell-based immunotherapies and related healthcare solutions. The company operates primarily through two segments: immune cell therapy and umbilical cord blood unit (CBU) banking services alongside related therapeutic applications. Through its subsidiaries, it engages in research, development, and provision of specialized cellular products, intellectual property licensing, and depository services for biological materials to serve clinical and therapeutic healthcare clients.

The company maintains operational and corporate activities across Singapore and Malaysia, utilizing specialized laboratory equipment, freehold land, and leased operational premises to conduct research and banking activities. Its subsidiaries include CytoMed Therapeutics (Malaysia) Sdn. Bhd., Longevity Bank Pte. Ltd., Advance Cancer Centre Pte. Ltd., IPSC Depository Sdn. Bhd., and Puricell Lab Pte. Ltd. CytoMed Therapeutics Limited maintains its principal executive offices and headquarters in Singapore.

Summary of the business section of CytoMed Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
CytoMed Therapeutics Ltd
Founded
2018
Headquarters
1 Commonwealth Lane, U0
Address
#08-22 One Commonwealth 149544
Phone
603824911
Website
cytomed.sg
Employees
5, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
U0
Fiscal year ends
December 31
Auditor
WWC, P.C., San Mateo, California

Stock & identifiers

Ticker
GDTC
Exchange
Nasdaq
IPO date
Apr 17, 2023
Shares outstanding
12M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
1873093
CUSIP
Y1R80M106
FIGI
BBG01BM32FR8
Share class FIGI
BBG01BM32GN0
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Yvonne GohChief Financial Officer25,781
Yoong Ying TanChief Corporate Officer25,781
Chee Kong ChooDirector2,899,746
Keng Kiat TohDirector4,000
Mark Kei Wei LeongDirector–
Chak Hua YewDirector2,469

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 17, 2023
Exchange
Nasdaq
First trading day
Apr 14, 2023
First-day close
$4.00
Lock-up ends (est.)
Oct 11, 2023

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“Employers with fewer than 5 employees will be granted a 6-month deferment period, making the new wage effective August 1, 2025.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 17, 2023IPOInitial public offering priced (424B4 prospectus)
Mar 30, 2023ListingRegistration of securities on an exchange (Form 8-A)
Nov 30, 2022Name changeName changed from CytoMed Therapeutics Pte. Ltd. to CytoMed Therapeutics Ltd

See a number that looks wrong?